The estimated Net Worth of Seth Lederman is at least $1.29 Milione dollars as of 29 June 2022. Seth Lederman owns over 20,000 units of Tonix Pharmaceuticals Corp stock worth over $3,635 and over the last 12 years he sold TNXP stock worth over $0. In addition, he makes $1,288,270 as Chairman of the Board, President e Chief Executive Officer at Tonix Pharmaceuticals Corp.
Seth has made over 35 trades of the Tonix Pharmaceuticals Corp stock since 2013, according to the Form 4 filled with the SEC. Most recently he bought 20,000 units of TNXP stock worth $34,200 on 29 June 2022.
The largest trade he's ever made was buying 100,000 units of Tonix Pharmaceuticals Corp stock on 25 March 2022 worth over $25,000. On average, Seth trades about 10,954 units every 62 days since 2013. As of 29 June 2022 he still owns at least 24,235 units of Tonix Pharmaceuticals Corp stock.
You can see the complete history of Seth Lederman stock trades at the bottom of the page.
Dr. Seth Lederman M.D. serves as Chairman of the Board, President, Chief Executive Officer of the Company. since October 7, 2011. He founded Tonix Pharmaceuticals, Inc., a wholly-owned subsidiary of the Company (“Tonix Sub”) in 2007 and has acted as its Chairman of the Board of Directors since its inception and as President since 2010. Dr. Lederman is an inventor on key patents and patent applications underlying our programs including: TNX-102 SL’s eutectic composition; Tonmya’s pharmacokinetic profile and related therapeutic properties, and Tonmya for posttraumatic stress disorder (PTSD). Dr. Lederman served as an Associate Professor at Columbia University, between 1996 and 2017. As an Assistant Professor at Columbia, Dr. Lederman discovered and characterized the CD40-ligand and invented therapeutic candidates to treat autoimmune diseases and transplant rejection. Dr. Lederman has been a Manager of L&L Technologies LLC, or L&L, since 1996. In addition, Dr. Lederman has been the Managing Member of Seth Lederman Co, LLC since 2007 and the Managing Member of Lederman & Co, LLC, or Lederman & Co, since 2002, both of which are biopharmaceutical consulting and investing companies. Dr. Lederman has also been the Managing Member of Targent Pharmaceuticals, LLC, or Targent, since 2000, and Managing Member of Plumbline LLC since 2002. Targent was a founder of Targent Pharmaceuticals Inc. on which Board of Directors Dr. Lederman served from inception in 2001 until the sale of its assets to Spectrum Pharmaceuticals Inc. Between 2007 and 2008, Dr. Lederman was Chairman of Validus Pharmaceuticals, Inc. and Fontus Pharmaceuticals, Inc. Dr. Lederman received his BA degree in Chemistry from Princeton University in 1979 and his MD from Columbia University in 1983.
As the Chairman of the Board, President e Chief Executive Officer of Tonix Pharmaceuticals Corp, the total compensation of Seth Lederman at Tonix Pharmaceuticals Corp is $1,288,270. There are no executives at Tonix Pharmaceuticals Corp getting paid more.
Seth Lederman is 62, he's been the Chairman of the Board, President e Chief Executive Officer of Tonix Pharmaceuticals Corp since 2011. There are 7 older and 8 younger executives at Tonix Pharmaceuticals Corp. The oldest executive at Tonix Pharmaceuticals Holding Corp is Adeoye Olukotun, 75, who is the Independent Director.
Seth's mailing address filed with the SEC is 509 Madison Ave #306, New York, NY 10022, USA.
Over the last 12 years, insiders at Tonix Pharmaceuticals Corp have traded over $155,884 worth of Tonix Pharmaceuticals Corp stock and bought 1,820,071 units worth $3,399,062 . The most active insiders traders include Ernest Mario, Seth Lederman e Bruce Daugherty. On average, Tonix Pharmaceuticals Corp executives and independent directors trade stock every 32 days with the average trade being worth of $2,734. The most recent stock trade was executed by Seth Lederman on 29 June 2022, trading 20,000 units of TNXP stock currently worth $34,200.
tonix is developing innovative pharmaceutical products to address major public health challenges. in addition to tonmya for ptsd, tonix is developing tnx-601 (tianeptine oxalate), a clinical candidate at pre-ind (investigational new drug) application stage, designed as a daytime treatment for ptsd and tnx-801, a live synthetic version of horsepox virus, at the pre-ind application stage, to be developed as a potential smallpox-preventing vaccine. further information about tonix can be found at www.tonixpharma.com.
Tonix Pharmaceuticals Corp executives and other stock owners filed with the SEC include: